PMC:1064873 / 7375-7544 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue
T6854	123-127	UMLS/C0444504	denotes	± s
T6852	123-127	UMLS/C2348143	denotes	± s
T6833	64-72	UMLS/C1555900	denotes	ical par
T6828	73-83	UMLS/C1704769	denotes	meters in
T6825	114-121	UMLS/C0332283	denotes	ows (me
T6823	114-121	UMLS/C0332282	denotes	ows (me
T6819	64-72	UMLS/C1611832	denotes	ical par
T6812	97-105	UMLS/C1705908	denotes	ents wer
T6801	64-72	UMLS/C1608518	denotes	ical par
T6791	91-96	UMLS/C1705923	denotes	y pat
T6788	64-72	UMLS/C0205210	denotes	ical par
T6769	73-83	UMLS/C2350001	denotes	meters in
T6768	73-83	UMLS/C0449381	denotes	meters in
T6760	114-121	UMLS/C1719822	denotes	ows (me
T6754	97-105	UMLS/C1550655	denotes	ents wer
T6738	91-96	UMLS/C0557651	denotes	y pat
T6730	25-62	UMLS/C0242708	denotes	ase-modifying antirheumatic drugs. Cl
T6725	123-127	UMLS/C1704970	denotes	± s
T6703	91-96	UMLS/C0008972	denotes	y pat
T6701	91-96	UMLS/C0008976	denotes	y pat
T6695	123-127	UMLS/C0876919	denotes	± s
T6691	13-19	UMLS/C0439423	denotes	ay) an
T6688	13-19	UMLS/C0439422	denotes	ay) an
T6684	91-96	UMLS/C2603343	denotes	y pat
T6682	91-96	UMLS/C2349977	denotes	y pat
T6674	97-105	UMLS/C0030705	denotes	ents wer
T6659	97-105	UMLS/C1578479	denotes	ents wer
T6650	97-105	UMLS/C1578483	denotes	ents wer
T6638	97-105	UMLS/C1578480	denotes	ents wer
T6629	97-105	UMLS/C1578481	denotes	ents wer
T6620	97-105	UMLS/C1578486	denotes	ents wer
T6611	97-105	UMLS/C1578484	denotes	ents wer
T6602	97-105	UMLS/C1578485	denotes	ents wer
T6587	91-96	UMLS/C1880229	denotes	y pat
T6568	131-149	UMLS/C0871420	denotes	ard deviation): er
T6566	73-83	UMLS/C0549193	denotes	meters in
T6565	91-96	UMLS/C0947630	denotes	y pat
T6562	123-127	UMLS/C2347634	denotes	± s

Id	Subject	Object	Predicate	Lexical cue
T6952	119-123	JJ	denotes	mean
T6951	118-119	-LRB-	denotes	(
T6950	110-117	VB	denotes	follows
T6949	107-109	RB	denotes	as
T6948	102-106	VB	denotes	were
T6947	93-101	NN	denotes	patients
T6946	87-92	NN	denotes	study
T6945	83-86	DT	denotes	the
T6944	80-82	IN	denotes	in
T6943	69-79	NN	denotes	parameters
T6942	60-68	JJ	denotes	Clinical
T6941	53-58	NN	denotes	drugs
T6940	39-52	JJ	denotes	antirheumatic
T6939	21-38	JJ	denotes	disease-modifying
T6938	17-20	CC	denotes	and
T6937	15-16	-RRB-	denotes	)
T6936	9-15	NN	denotes	mg/day
T6935	5-8	CD	denotes	7.5
T6934	3-4	SYM	denotes	≤
T6933	2-3	-LRB-	denotes	(
T6958	147-158	NN	denotes	erythrocyte
T6957	145-146	-COLON-	denotes	:
T6956	144-145	-RRB-	denotes	)
T6955	135-144	NN	denotes	deviation
T6954	126-134	JJ	denotes	standard
T6953	124-125	JJ	denotes	±
R3253	T6935	T6934	arg1Of	7.5,≤
R3254	T6936	T6933	arg2Of	mg/day,(
R3255	T6936	T6935	arg1Of	mg/day,7.5
R3256	T6937	T6933	arg3Of	),(
R3258	T6941	T6938	arg2Of	drugs,and
R3259	T6941	T6939	arg1Of	drugs,disease-modifying
R3260	T6941	T6940	arg1Of	drugs,antirheumatic
R3261	T6943	T6942	arg1Of	parameters,Clinical
R3262	T6943	T6944	arg1Of	parameters,in
R3263	T6943	T6950	arg1Of	parameters,follows
R3264	T6946	T6944	arg2Of	study,in
R3265	T6946	T6945	arg1Of	study,the
R3266	T6946	T6948	arg2Of	study,were
R3267	T6947	T6948	arg1Of	patients,were
R3268	T6950	T6949	arg1Of	follows,as
R3269	T6950	T6951	arg1Of	follows,(
R3270	T6950	T6957	arg1Of	follows,:
R3273	T6955	T6951	arg2Of	deviation,(
R3274	T6955	T6952	arg1Of	deviation,mean
R3275	T6955	T6953	arg1Of	deviation,±
R3276	T6955	T6954	arg1Of	deviation,standard
R3277	T6956	T6951	arg3Of	),(

Id	Subject	Object	Predicate	Lexical cue
T7310	21-58	Entity	denotes	disease-modifying antirheumatic drugs
T7304	147-158	Entity	denotes	erythrocyte

Id	Subject	Object	Predicate	Lexical cue
T7168	147-158	VB	denotes	erythrocyte
T7167	145-146	:	denotes	:
T7166	144-145	-RRB-	denotes	)
T7165	135-144	NN	denotes	deviation
T7164	126-134	JJ	denotes	standard
T7163	124-125	JJ	denotes	±
T7162	119-123	VB	denotes	mean
T7161	118-119	-LRB-	denotes	(
T7160	110-117	VBZ	denotes	follows
T7159	107-109	IN	denotes	as
T7158	102-106	VBD	denotes	were
T7157	93-101	NNS	denotes	patients
T7156	87-92	NN	denotes	study
T7155	83-86	DT	denotes	the
T7154	80-82	IN	denotes	in
T7153	69-79	NNS	denotes	parameters
T7152	60-68	JJ	denotes	Clinical
T7151	58-59	.	denotes	.
T7150	53-58	NNS	denotes	drugs
T7149	39-52	JJ	denotes	antirheumatic
T7148	21-38	JJ	denotes	disease-modifying
T7147	17-20	CC	denotes	and
T7146	15-16	-RRB-	denotes	)
T7145	9-15	NN	denotes	mg/day
T7144	5-8	CD	denotes	7.5
T7143	3-4	CD	denotes	≤
T7142	2-3	-LRB-	denotes	(
R3461	T7144	T7145	nummod	7.5,mg/day
R3462	T7145	T7143	appos	mg/day,≤
R3463	T7146	T7145	punct	),mg/day
R3464	T7147	T7145	cc	and,mg/day
R3465	T7148	T7150	amod	disease-modifying,drugs
R3466	T7149	T7150	amod	antirheumatic,drugs
R3467	T7150	T7145	conj	drugs,mg/day
R3469	T7152	T7153	amod	Clinical,parameters
R3470	T7153	T7158	nsubj	parameters,were
R3471	T7154	T7153	prep	in,parameters
R3472	T7155	T7157	det	the,patients
R3473	T7156	T7157	compound	study,patients
R3474	T7157	T7154	pobj	patients,in
R3475	T7158	T7158	ROOT	were,were
R3476	T7159	T7160	mark	as,follows
R3477	T7160	T7158	advcl	follows,were
R3478	T7161	T7162	punct	(,mean
R3480	T7163	T7165	nmod	±,deviation
R3481	T7164	T7165	amod	standard,deviation
R3482	T7165	T7162	dobj	deviation,mean
R3483	T7166	T7162	punct	),mean
R3484	T7167	T7162	punct	:,mean